转移性头癌:免疫疗法及其他方面
Kirsten V Nguyen1, Cody M Lebeck Lee2, Jennifer H Choe3
1Vanderbilt University, School of Medicine, Nashville, TN.
Seminars in radiation oncology
|March 16, 2025
概括
免疫疗法为头癌患者提供了更好的结果,但反应率低于最佳水平. 未来的研究重点是新的目标和平台,以提高转移性和复发性环境中的治疗疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 头癌每年导致大量的诊断和死亡.
- 转移性疾病占头癌病例的很大一部分.
- 免疫疗法已成为转移性和复发性头恶性瘤的关键治疗方式.
研究的目的:
- 审查当前针对头癌的免疫疗法的情况.
- 探索头癌免疫治疗的未来方向和新的治疗策略.
- 确定新兴的目标和平台,以改善治疗结果.
主要方法:
- 对当前免疫疗法治疗方法的文献综述.
- 对头癌患者的反应率和结果的分析.
- 讨论正在进行的研究和未来的治疗途径.
主要成果:
- 免疫疗法改善了结果,但表现出不理想的反应率 (13%-20%).
- 在一小部分患者中观察到持久的反应.
- 目前的治疗方法是基石,但仍有改进的余地.
结论:
- 免疫疗法是头癌治疗的重要组成部分,但仍然存在挑战.
- 对新的目标和治疗平台进行进一步的研究至关重要.
- 未来的战略旨在提高晚期疾病患者的应答率和长期疗效.
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Cancer Vaccines
319
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
319
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cytotoxic T Cells-mediated Immune Response
823
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
823


